A recent study published in the ACR Open Rheumatology journal explored the effectiveness of guselkumab in treating patients with psoriatic arthritis (PsA). The study evaluated patient-reported outcomes after 6 months of on-label guselkumab use and provided valuable insights into its real-world effectiveness.
Psoriatic arthritis is a chronic inflammatory disease that affects the joints and skin that causes pain, stiffness and swelling. Despite advancements in treatment, many patients continue to struggle with symptoms that leads to decreased quality of life.
The study included participants from the CorEvitas Registry who initiated and persisted with guselkumab treatment and focused on key patient-reported outcomes such as pain, patient global assessment of arthritis and psoriasis and physical function.
The results from the analysis revealed that of the patients who persisted with on-label guselkumab treatment for 6 months, a significant proportion experienced clinically meaningful improvements in pain and physical function. Approximately 40% of patients reported at least a 15-mm reduction in pain scores while around 30% achieved improvements in physical function scores.
The study population consisted mainly of patients with treatment-resistant PsA by indicating the potential of guselkumab as a viable treatment option for those who have not responded well to previous therapies. This unveiled the importance of exploring alternative treatment options for PsA patients who may have limited choices due to treatment resistance.
The study also emphasized that pain and physical function are crucial factors which impact the overall quality of life for PsA patients. The outcomes demonstrate that guselkumab holds promise in addressing these key aspects of the disease which could improve outcomes and management of PsA symptoms.
Source:
Mease, P. J., Ogdie, A., Tesser, J., Shiff, N. J., Zhao, R. S., Chakravarty, S. D., Kelleman, M., Dodge, R., McLean, R. R., Broadwell, A., Kavanaugh, A., & Merola, J. F. (2024). Improvements in Patient‐Reported Outcomes Through Six Months of Guselkumab Treatment in Patients With Active Psoriatic Arthritis: Real‐WorldData From the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. In ACR Open Rheumatology. Wiley. https://doi.org/10.1002/acr2.11657